Diffuse Midline Glioma

Disease

Related News

Artios expands leadership team as alnodesertib moves toward late-stage development

May 05, 2026

Artios added six senior leaders in 2026 as alnodesertib moved toward late-stage development and potential U.S. commercialization. The company is also running a Phase 2 study of ART6043.

Australia launches world-first mRNA vaccine trial for pediatric brain cancer

Feb 24, 2026

Southern RNA and Providence Therapeutics will support a clinical trial testing personalized mRNA cancer vaccines for children with treatment-resistant brain tumors, marking the first multi-site pediatric study of its kind.